Kane Biotech Inc. (KNE.V)
CAD 0.08
(-6.25%)
CAD 0.08
(-6.25%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.04 CAD | -11.49% |
| 2022 | -0.03 CAD | 21.27% |
| 2021 | -0.04 CAD | -18.21% |
| 2020 | -0.03 CAD | -195.73% |
| 2019 | -0.01 CAD | 71.25% |
| 2018 | -0.04 CAD | 10.55% |
| 2017 | -0.05 CAD | 32.69% |
| 2016 | -0.07 CAD | 13.33% |
| 2015 | -0.08 CAD | 8.13% |
| 2014 | -0.08 CAD | -5.6% |
| 2013 | -0.08 CAD | 19.6% |
| 2012 | -0.10 CAD | -2.77% |
| 2011 | -0.10 CAD | 11.55% |
| 2010 | -0.11 CAD | 15.38% |
| 2009 | -0.13 CAD | 31.58% |
| 2008 | -0.19 CAD | 26.92% |
| 2007 | -0.26 CAD | 0.0% |
| 2006 | -0.26 CAD | 16.13% |
| 2005 | -0.31 CAD | -40.91% |
| 2004 | -0.22 CAD | -4.76% |
| 2003 | -0.21 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.01 CAD | 8.62% |
| 2024 Q2 | 0.07 CAD | 754.72% |
| 2023 FY | - CAD | -22.98% |
| 2023 Q1 | -0.01 CAD | -37.14% |
| 2023 Q2 | -0.01 CAD | 19.79% |
| 2023 Q4 | -0.01 CAD | -6.42% |
| 2023 Q3 | -0.01 CAD | -41.56% |
| 2022 Q3 | -0.01 CAD | -7.79% |
| 2022 Q4 | -0.01 CAD | 15.66% |
| 2022 Q2 | -0.01 CAD | 20.62% |
| 2022 Q1 | -0.01 CAD | 12.61% |
| 2022 FY | - CAD | 21.27% |
| 2021 Q1 | -0.01 CAD | -10.53% |
| 2021 Q3 | -0.01 CAD | -64.2% |
| 2021 Q4 | -0.01 CAD | 16.54% |
| 2021 Q2 | -0.01 CAD | 3.57% |
| 2021 FY | - CAD | -18.21% |
| 2020 Q2 | -0.00 CAD | 64.12% |
| 2020 Q4 | -0.01 CAD | 20.0% |
| 2020 Q3 | -0.01 CAD | -102.13% |
| 2020 Q1 | -0.01 CAD | -5.65% |
| 2020 FY | - CAD | -195.73% |
| 2019 Q2 | 0.02 CAD | 343.9% |
| 2019 Q3 | -0.01 CAD | -149.5% |
| 2019 Q4 | -0.01 CAD | -25.25% |
| 2019 FY | - CAD | 71.25% |
| 2019 Q1 | -0.01 CAD | 2.38% |
| 2018 Q4 | -0.01 CAD | 32.26% |
| 2018 Q1 | -0.01 CAD | 15.91% |
| 2018 Q2 | -0.01 CAD | 20.72% |
| 2018 FY | - CAD | 10.55% |
| 2018 Q3 | -0.01 CAD | -40.91% |
| 2017 Q4 | -0.01 CAD | -11.86% |
| 2017 FY | - CAD | 32.69% |
| 2017 Q3 | -0.01 CAD | 31.79% |
| 2017 Q1 | -0.01 CAD | 62.04% |
| 2017 Q2 | -0.02 CAD | -232.69% |
| 2016 FY | - CAD | 13.33% |
| 2016 Q4 | -0.01 CAD | 22.16% |
| 2016 Q2 | -0.03 CAD | -17.7% |
| 2016 Q3 | -0.02 CAD | 38.46% |
| 2016 Q1 | -0.02 CAD | -10.45% |
| 2015 Q2 | -0.02 CAD | 22.11% |
| 2015 Q4 | -0.02 CAD | -15.18% |
| 2015 FY | - CAD | 8.13% |
| 2015 Q3 | -0.02 CAD | -23.23% |
| 2015 Q1 | -0.02 CAD | 17.77% |
| 2014 Q4 | -0.02 CAD | -32.24% |
| 2014 Q1 | -0.02 CAD | -139.13% |
| 2014 Q3 | -0.02 CAD | 33.45% |
| 2014 Q2 | -0.03 CAD | -66.67% |
| 2014 FY | - CAD | -5.6% |
| 2013 Q3 | -0.02 CAD | 2.21% |
| 2013 Q1 | -0.04 CAD | -23.75% |
| 2013 FY | - CAD | 19.6% |
| 2013 Q4 | -0.01 CAD | 61.02% |
| 2013 Q2 | -0.02 CAD | 51.08% |
| 2012 Q1 | -0.02 CAD | 2.65% |
| 2012 Q3 | -0.03 CAD | -12.35% |
| 2012 Q4 | -0.03 CAD | -6.03% |
| 2012 FY | - CAD | -2.77% |
| 2012 Q2 | -0.03 CAD | -14.09% |
| 2011 Q1 | -0.04 CAD | -73.76% |
| 2011 FY | - CAD | 11.55% |
| 2011 Q3 | -0.02 CAD | -51.85% |
| 2011 Q2 | -0.02 CAD | 57.81% |
| 2011 Q4 | -0.02 CAD | 8.13% |
| 2010 Q2 | -0.03 CAD | 14.63% |
| 2010 Q1 | -0.03 CAD | -132.62% |
| 2010 Q4 | -0.02 CAD | 28.71% |
| 2010 Q3 | -0.03 CAD | -10.71% |
| 2010 FY | - CAD | 15.38% |
| 2009 FY | - CAD | 31.58% |
| 2009 Q1 | -0.04 CAD | -28.36% |
| 2009 Q4 | -0.01 CAD | 67.81% |
| 2009 Q2 | -0.04 CAD | -24.08% |
| 2009 Q3 | -0.04 CAD | 0.0% |
| 2008 Q1 | -0.04 CAD | 30.86% |
| 2008 FY | - CAD | 26.92% |
| 2008 Q4 | -0.03 CAD | 68.57% |
| 2008 Q3 | -0.09 CAD | -20.52% |
| 2008 Q2 | -0.07 CAD | -62.05% |
| 2007 Q1 | -0.05 CAD | 47.21% |
| 2007 Q2 | -0.10 CAD | -95.93% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q3 | -0.05 CAD | 47.41% |
| 2007 Q4 | -0.06 CAD | -27.81% |
| 2006 Q2 | -0.06 CAD | -30.64% |
| 2006 FY | - CAD | 16.13% |
| 2006 Q1 | -0.05 CAD | 44.31% |
| 2006 Q4 | -0.09 CAD | -82.39% |
| 2006 Q3 | -0.05 CAD | 16.78% |
| 2005 Q4 | -0.08 CAD | -10.33% |
| 2005 Q1 | -0.07 CAD | 20.74% |
| 2005 Q2 | -0.08 CAD | -19.25% |
| 2005 Q3 | -0.08 CAD | 3.53% |
| 2005 FY | - CAD | -40.91% |
| 2004 Q4 | -0.08 CAD | -115.68% |
| 2004 Q3 | -0.04 CAD | 33.16% |
| 2004 Q2 | -0.06 CAD | -38.24% |
| 2004 FY | - CAD | -4.76% |
| 2004 Q1 | -0.04 CAD | -85.46% |
| 2003 Q2 | -0.00 CAD | 0.0% |
| 2003 Q3 | -0.07 CAD | -22866.67% |
| 2003 FY | - CAD | 0.0% |
| 2003 Q4 | -0.02 CAD | 67.05% |
| Name | Eps | Eps Difference |
|---|---|---|
| Arch Biopartners Inc. | -0.05 CAD | 32.645% |
| Covalon Technologies Ltd. | -0.18 CAD | 80.056% |
| Hemostemix Inc. | -0.03 CAD | -18.482% |
| Universal Ibogaine Inc. | -0.06 CAD | 36.46% |
| MedMira Inc. | -0.00 CAD | -844.737% |
| Marvel Biosciences Corp. | -0.06 CAD | 37.889% |
| NervGen Pharma Corp. | -0.38 CAD | 90.553% |
| XORTX Therapeutics Inc. | -1.44 CAD | 97.507% |